BONDUELLE Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number : 447 250 044 ( Dunkerque Commercial and Companies Register) 2024-2025 Annual Sales(July 1, 2024 - June 30, 2025) The Bonduelle Group reports growth in Quarter 4 and confirms its annual profitability objective The Bonduelle Group sales for FY 2024-2025 (ending June 30, 2025) amounted to 2,203.8 million euros, a variation of -0.8 ...

Core Viewpoint - The Bonduelle Group has confirmed the sale of its packaged salad business in France to the LSDH Group, effective July 17, 2025, as part of a strategic move to focus on fresh delicatessen markets amid declining salad consumption in France [2][3][4]. Group 1: Sale Details - The sale of the packaged salad business was initially announced on August 29, 2024, and became effective on July 17, 2025 [2][3]. - The divested business represented approximately 3.5% of Bonduelle's turnover, equating to €80 million for the 2024-2025 financial year [4]. Group 2: Strategic Focus - The Bonduelle Group aims to accelerate its activities in the fresh delicatessen market in France and Europe following the divestment [3][4]. - The LSDH Group will continue to use the Bonduelle brand for packaged salads in France through a licensing agreement [3][4]. Group 3: LSDH Group Overview - The LSDH Group is a family business with over 100 years of history, operating in six regions with ten production sites in France [8][9]. - The group employs 2,250 individuals and emphasizes social, societal, and environmental commitments in its operations [9].

Group 1 - Bon Natural Life Limited (BON) has entered a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co., Ltd. for a term of 24 months, with a total contract value of up to US$16 million [1] - The agreement allows Huahai Keyuan to market, sell, and distribute BON's natural prebiotic series products in the Chinese market [1] - BON's latest natural prebiotic product series features a "Prebiotic + Postbiotic" complex centered on super prebiotic stachyose, aimed at enhancing gut health by promoting beneficial probiotic populations [2][3] Group 2 - The partnership with Huahai Keyuan is expected to accelerate BON's entry into China's growing gut health market and unlock substantial growth opportunities for both companies [4] - Yongwei Hu, Chairman and CEO of BON, emphasized the strategic collaboration's potential to drive top-line growth and long-term shareholder value [4] - Huahai Keyuan is recognized for its strong market presence and expertise in introducing innovative health products to the Chinese market [4]

XI’AN, China, June 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“Bon” or the “Company”), a leading bio-ingredient solutions provider for natural, health, and personal care industries, today announced a non-exclusive sales distribution agreement with Tianjin Merrill-Youli Trading Co., Ltd., a prominent Asia-Pacific fragrance chemical distributor (“Merrill-Youli”). The term of the agreement is 36 months with a total contract value of up to US$18 million. Pursuant to the agreement, Merr ...

XI’AN, China, June 03, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced its board of directors approved a share repurchase program pursuant to which the Company may purchase up to $1.0 million of its Class A ordinary shares. Under the share repurchase program, the Company is authorized to repurchase its shares from time to time in the open market. The timing ...

XI’AN, China, May 22, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade Co., Ltd., a leading functional ingredient distributor in China. The term of the Agreement is 24 months with a total contract value of US$ 24 million. Pursuant to the agreement, Shanghai Risesun will mark ...

XI’AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd., a leading functional ingredient distributor in China. The term of the agreement is 36 months with a total contract value of 32 million US dollars. Pursuant to the agreement, Beijing Huahai Keyuan will serve as the ex ...

Core Viewpoint - Bon Natural Life Limited will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement of $1.00, effective May 19, 2025 [3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 25 issued and outstanding Class A ordinary shares into one new Class A ordinary share, with no fractional shares issued [1]. - The new CUSIP number for the Class A ordinary shares post-split will be G14492204, and trading will continue under the existing symbol "BON" [2]. - The authorized share capital will increase to 1,000,000,000 Class A ordinary shares, 50,000,000 Class B ordinary shares, and 50,000,000 preference shares [4]. Group 2: Class Rights and Shareholder Approval - The conversion rate for Class B ordinary shares will change from a 1:1 basis to a 1:25 basis for conversion into Class A ordinary shares [5]. - The reverse stock split and related changes were approved by shareholders during an extraordinary general meeting on April 15, 2025 [6].

Core Viewpoint - BON Natural Life Limited has launched a new sleep health product series utilizing a proprietary delivery system aimed at enhancing the bio-activity of glucoraphanin, a compound found in broccoli, to improve health benefits [1][3][4] Group 1: Product Development - The new product series is developed using the "Glucoraphanin-Myrosinase" delivery system, which is patent-pending and designed to enhance the absorption and utilization of glucoraphanin in the body [1][3] - The delivery system aims to improve the conversion efficiency of glucoraphanin to sulforaphane, addressing challenges related to bio-availability [3][4] Group 2: Health Benefits - Glucoraphanin is linked to various health benefits, including anti-cancer properties, sleep regulation, neuro-protective effects, digestive health support, anti-inflammatory, antioxidant, and anti-aging effects [2] - The enzymatic conversion of glucoraphanin to sulforaphane is typically inefficient, which limits the health benefits derived from broccoli [2] Group 3: Market Potential - The company anticipates that the new sleep health products will achieve market expansion and significantly impact the sleep health market dynamics [4] - The innovative delivery system is expected to combine scientific rigor with commercial potential, addressing unmet needs in sleep health [4]

BONDUELLE Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number : 447 250 044 ( Dunkerque Commercial and Companies Register) Quarter 3 FY 2024-2025 Sales (January 1 - March 31, 2025) The Bonduelle Group confirms its annuals objectives and posts stability in its business activity for Quarter 3 The Bonduelle Group sales for Quarter 3 (January 1 - March 31, 2025) of FY 2024-2025, were stable com ...